PDCD1 and head and neck squamous cell carcinoma: Clinical trials have established that the administration of immune checkpoint inhibitors targeting PD-1, such as Pembrolizumab and Nivolumab, significantly improves survival in recurrent or metastatic HNSCC regardless of the HPV status [16,221].